获得性反应性穿通性胶原病的研究进展  

Research progress on acquired reactive penetrating collagenosis

作　　者：白璐[1] 朱才勇[1] BAI Lu;ZHU Caiyong(Department of Dermatology,the Hospital of NO.80 Group Army of PLA,Weifang 261021,China)

机构地区：[1]中国人民解放军陆军第八十集团军医院皮肤病科,山东潍坊261021

出　　处：《皮肤病与性病》2024年第5期302-305,共4页Dermatology and Venereology

摘　　要：获得性反应性穿通性胶原病(ARPC)是一种后天性的穿通性皮肤病,皮肤病变主要由脐部凹陷丘疹或结节组成,中心有粘性角化塞或结痂。目前其发病机制尚不清楚,反复创伤和微血管病被认为是主要的致病因素。近年来发现ARPC患者皮损μ-阿片受体过度表达、IL-31水平升高,药物如二肽基肽酶-4抑制剂、抗表皮生长因子受体抑制剂及文身等均可诱发ARPC。最近国内外学者使用度普利尤单抗、奈莫利珠单抗、伊曲康唑、过氧化苯甲酰乳膏等治疗ARPC取得了良好的疗效,笔者对ARPC的发病机制和治疗研究进展进行了综述。Acquired reactive perforating collagenosis(ARPC)is an acquired penetrating skin disease,with skin lesions mostly consisting of umbilical concave papules or nodules,with adhesive keratinization plugs or crusts in the center.The pathogenesis is unclear,and recurrent trauma and microvascular disease are considered the main pathogenic factors.In recent years,it has been found that ARPC patients had overexpression ofμ-opioid receptors in their skin lesions,elevated level of IL-31,and drugs such as dipeptidylpeptidase-4 inhibitors,anti epidermal growth factor receptor inhibitors,and tattoos can all induce ARPC.Recently,scholars at home and abroad had used duplizumab,nemolizumab,itraconazole and benzoyl peroxide cream to treat ARPC and had achieved good therapeutic effects.The author reviews the pathogenesis and treatment research progress of ARPC.

关 键 词：获得性反应性穿通性胶原病 发病机制 度普利尤单抗 奈莫利珠单抗 

分 类 号：R758.6[医药卫生—皮肤病学与性病学]